Objective To investigate the expression and clinical significance of budding uninhibit-ed by benzimidazoles-1(Bub1) and mitotic arrest deficient-2 (Mad2) protein in endometrium ,complex hy-perplasia and endometrial carcinoma . Methods The expression of Bub1 and Mad2 protein in 72 cases of endometrial carcinoma (group A ) ,40 cases of complex endometrial hyperplasia (group B ) and 40 cases of endometrial(group C) were detected by Immunohistochemistal SP method ,and the relationship between the expression of Bub1 ,Mad2 protein and the clinical stage ,pathological classification and lymph node me-tastasis of endometrial carcinoma patients was analysed . Results (1) The positive rate of Bub1 in A ,B , C groups were 27 .78% ,57 .50% ,85 .00% respectively ,positive expression rate between the three groups was statistically significant (P< 0 .05) . In group A ,different clinical stage or pathologic stage in pa-tients ,the positive expression rate was statistically significant difference (P<0 .05);In group A ,with or without lymph node metastasis in patients ,the positive expression rate was no statistically significant difference (P> 0 .05) . (2) The positive rate of Mad2 in A ,B ,C groups were 86 .11% ,57 .50% , 22 .50% respectively , positive expression rate between the three groups was statistically significant (P<0 .05) . In group A ,different pathological grading in patients ,the positive expression rate was statis-tically significant difference (P< 0 .05);In group A ,different clinical stages and with or without lymph node metastases in patients ,the positive expression rate there was no statistically significant difference (P>0 .05) . (3)The expression of Bub1 and Mad2 protein negatively correlated in endometrial carcinoma (r= -0 .448 ,P<0 .01) . Conclusion The interaction of Bub1 with Mad2 proteins may play an impor-tant role in the pathological process of endometrial carcinoma .%目的探讨苯并咪唑出芽抑制解除同源物蛋白-1（Bub1）和有丝分裂阻滞缺陷蛋白-2（Mad2）在人子宫内膜癌中的表达情况。方法采用免疫组织化学S P法分别检测72例子宫内膜癌组织（A组）、40例子宫内膜不典型增生组织（B组）和40例人正常子宫内膜组织（C组）中Bub1和M ad2蛋白的表达情况，并分析其与子宫内膜癌患者的临床分期、病理分级和淋巴结转移的关系。结果（1）Bub1蛋白在 A ，B ，C组的阳性表达率分别为27．78％，57．50％，85．00％，3组间比较差别有统计学意义（ P＜0．05）；A组中，不同临床分期或病理分级患者的Bub1蛋白阳性表达率差别有统计学意义（P＜0．05），有、无淋巴结转移患者的阳性表达率差别无统计学意义（P＞0．05）。（2）M ad2蛋白在A ，B ，C组的阳性表达率分别为86．11％，57．50％，22．50％，3组间比较差别有统计学意义（P＜0．05）；A组中，不同病理分级患者的Mad2蛋白阳性表达率差别有统计学意义（P＜0．05），不同临床分期及有、无淋巴结转移患者的Mad2蛋白阳性表达率差别无统计学意义（P＞0．05）。（3）Bub1和Mad2蛋白在子宫内膜癌组织中的表达呈负相关（r＝-0．448，P＜0．01）。结论 Bub1和Mad2蛋白相互作用，在子宫内膜癌的发生、发展过程中可能起重要作用。
展开▼
